[go: up one dir, main page]

WO2010034006A3 - Micro-arn-101 suppresseur de tumeur putatif modulant l'epigenome cancereux par repression de la proteine ezh2 du groupe polycomb - Google Patents

Micro-arn-101 suppresseur de tumeur putatif modulant l'epigenome cancereux par repression de la proteine ezh2 du groupe polycomb Download PDF

Info

Publication number
WO2010034006A3
WO2010034006A3 PCT/US2009/057890 US2009057890W WO2010034006A3 WO 2010034006 A3 WO2010034006 A3 WO 2010034006A3 US 2009057890 W US2009057890 W US 2009057890W WO 2010034006 A3 WO2010034006 A3 WO 2010034006A3
Authority
WO
WIPO (PCT)
Prior art keywords
repressing
modulates
tumor suppressor
group protein
polycomb group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/057890
Other languages
English (en)
Other versions
WO2010034006A2 (fr
Inventor
Jeffrey J. Friedman
Gangning Liang
Peter A. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Priority to US13/119,699 priority Critical patent/US20110224284A1/en
Publication of WO2010034006A2 publication Critical patent/WO2010034006A2/fr
Publication of WO2010034006A3 publication Critical patent/WO2010034006A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne en général le profilage de micro-ARN pour certaines maladies. L'invention concerne plus particulièrement des méthodes et des compostions de micro-ARN destinées à inhiber la croissance et la formation de tumeurs.
PCT/US2009/057890 2008-09-22 2009-09-22 Micro-arn-101 suppresseur de tumeur putatif modulant l'epigenome cancereux par repression de la proteine ezh2 du groupe polycomb Ceased WO2010034006A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/119,699 US20110224284A1 (en) 2008-09-22 2009-09-22 Putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9911408P 2008-09-22 2008-09-22
US61/099,114 2008-09-22

Publications (2)

Publication Number Publication Date
WO2010034006A2 WO2010034006A2 (fr) 2010-03-25
WO2010034006A3 true WO2010034006A3 (fr) 2010-05-27

Family

ID=42040204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/057890 Ceased WO2010034006A2 (fr) 2008-09-22 2009-09-22 Micro-arn-101 suppresseur de tumeur putatif modulant l'epigenome cancereux par repression de la proteine ezh2 du groupe polycomb

Country Status (2)

Country Link
US (1) US20110224284A1 (fr)
WO (1) WO2010034006A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109745316B (zh) * 2012-04-13 2023-01-24 Epizyme股份有限公司 用于治疗癌症的联合治疗

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006577A2 (fr) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions et méthodes pour inhiber la protéine ezh2
EP2435570A1 (fr) * 2009-05-25 2012-04-04 Carola Ponzetto Thérapie de différenciation pour sarcomes
SG180031A1 (en) * 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
US20140107176A1 (en) * 2012-10-12 2014-04-17 Agency For Science, Technology And Research Method of modulating a prostate cancer cell
WO2020227604A1 (fr) * 2019-05-08 2020-11-12 Nova Southeastern University Régulation de la réparation d'excision de nucléotides (ner) par microarn pour le traitement du cancer du sein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554818A1 (fr) * 2004-02-09 2005-08-25 Thomas Jefferson University Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers
EP2290071B1 (fr) * 2004-05-28 2014-12-31 Asuragen, Inc. Procédés et compositions impliquant du microARN
WO2009006577A2 (fr) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions et méthodes pour inhiber la protéine ezh2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAUNDERS ET AL.: "Human polymorphism at microRNAs and microRNA target sites.", PNAS, vol. 104, no. 9, 2007, pages 3301 - 3305 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109745316B (zh) * 2012-04-13 2023-01-24 Epizyme股份有限公司 用于治疗癌症的联合治疗

Also Published As

Publication number Publication date
WO2010034006A2 (fr) 2010-03-25
US20110224284A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
WO2010037041A3 (fr) Agents se liant aux récepteurs frizzled et leurs utilisations
WO2010141738A3 (fr) Compositions et procédé pour inhiber la croissance d'une tumeur
WO2008154249A3 (fr) Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur her2
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
HK1210611A1 (en) Histone demethylase inhibitors
WO2018091740A3 (fr) Nouveaux anticorps et utilisations associées
WO2011103016A3 (fr) Compositions et méthodes d'inhibition d'ezh2
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
EA201001639A1 (ru) Композиции и способы их получения и применения
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2012058588A3 (fr) Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci
WO2012058592A3 (fr) Molécules non antagonistes se liant au récepteur egf et immunoconjugués de celles-ci
WO2012019024A3 (fr) Molécules se liant à her3 et leurs immunoconjugués
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
WO2009126310A3 (fr) Procédés d’identification et utilisation d’agents ciblant les cellules souches cancéreuses
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
BRPI0607203A2 (pt) anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
WO2009002947A3 (fr) Composés et peptides de liaison au récepteur de trail
WO2008089397A3 (fr) Marqueurs du cancer adrb2
WO2008152131A3 (fr) Inhibition par arni de l'expression du canal alpha-enac
WO2011082267A3 (fr) Composés triazolo-pyrazine substitués
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
WO2009142738A3 (fr) Compositions et procédés utilisables en matière de diagnostic et de traitement du cancer
WO2008061108A3 (fr) Dérivés de phtalazine
WO2010014253A3 (fr) Composés inhibiteurs d’ant4 et leurs procédés d’utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09815396

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13119699

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09815396

Country of ref document: EP

Kind code of ref document: A2